Bangalore, India -- (SBWire) -- 12/20/2017 --The vast majority of commercially available tissue valves are xenograft valves derived from animals. Usually, the valves are porcine, meaning from a pig, or bovine, meaning from a cow. The porcine heart is most similar to the human heart and therefore represents the best anatomical fit for replacement. The tissue of the pericardial sac is particularly well suited for a valve leaflet due to its extremely durable physical properties. Before implantation, the tissue undergoes multiple chemical treatments to make it suitable for replacement in the human heart. The tissue is sterilized so that the biological markers are removed, thereby eliminating a response from the host's immune system.
The primary advantage of tissue over mechanical valves is that tissue valves are much more biocompatible and thus a patient who receives a tissue valve does not require life-long anti-coagulation therapy. However, a disadvantage of tissue valves is that they are not as durable and typically last between 15 and 20 years before requiring replacement. Nevertheless, advances in polymer coatings have made tissue valves more durable than ever before. Furthermore, several aortic tissue valve replacement devices under development that are currently undergoing clinical trials in the U.S. or awaiting FDA approval may be implanted percutaneously.
Tissue valves, which are also known as bioprosthetic valves, are harvested from either human donors or animal tissue. Human tissue valves can either be obtained from donor cadavers in allograft procedures, or from one's own body in an autograft procedure. Allograft valves may be acquired from deceased family members or anonymous donors. Autograft valves may be obtained through a Ross procedure, whereby part of the pulmonary valve is grafted and harvested into the aortic position. Whether autograft or allograft, human donor valves involve complicated extraction and insertion procedures. Human tissue valves are in limited supply and typically do not function drastically better than xenograft valves.
Spanning over 395 pages "US Market Report for Tissue Heart Valves 2018 - MedCore" report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Tissue Heart Valve Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.
For more information Visit at: https://www.drugpipeline.net/idata-research/us-market-report-tissue-heart-valves-2018-medcore
Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare
Related Reports;
US Procedure Numbers for Cardiac Surgery and Heart Valve Devices 2018 - MedPro - Visit at - https://www.drugpipeline.net/idata-research/us-procedure-numbers-cardiac-surgery-and-heart-valve-devices-2018-medpro
US Product Portfolio for Cardiac Surgery and Heart Valve Devices 2018 - MedFolio - Visit at - https://www.drugpipeline.net/idata-research/us-product-portfolio-cardiac-surgery-and-heart-valve-devices-2018-medfolio
About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
US Market Report for Tissue Heart Valves 2018; New Report Launched
DrugPipeline.net has announced the addition of “US Market Report for Tissue Heart Valves 2018 - MedCore” research report to their website www.DrugPipeline.net